GlassScriptPhysician profile
Mark Kevin Emas
NPI 1053471987
$14,460.55
in general payments reported to CMS, 2019-2025
56 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2020: $1,661 · 2021: $2,248 · 2022: $2,666 · 2023: $2,184 · 2024: $1,850 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,783 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,782.55 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,465.04 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,182.54 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biogen, INC. | $984.91 | 2019-2025 | Leqembi, Tysabri, Vumerity |
| Amgen INC. | $980.53 | 2019-2025 | Uplizna, Aimovig |
| Allergan, INC. | $833.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $689.30 | 2019-2025 | |
| Genzyme Corporation | $603.88 | 2019-2023 | |
| Kyowa Kirin, INC. | $543.61 | 2020-2024 | Nourianz |
| Emd Serono, INC. | $488.65 | 2019-2023 | Mavenclad |
| Lilly USA, LLC | $480.80 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Pfizer INC. | $397.71 | 2023-2025 | |
| Lundbeck LLC | $377.12 | 2019-2025 | Vyepti, Rexulti |
| Merz Pharmaceuticals, LLC | $346.81 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Boston Scientific Corporation | $317.45 | 2022-2025 | Vercise |
| Biohaven Pharmaceutical Holding Company LTD. | $304.64 | 2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Emas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.